Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 8/20 | 0.39 |
| ▸ | MAOA | P21397 | 8/20 | 0.39 |
| ▸ | MAOB | P27338 | 8/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21242653 | 0.77 | NPC1 (0.43) | KDM1AMAOAMAOBNPC1RAB9A | |
| Methane SCHEMBL28832437 | 0.74 | NPC1 (0.36) | KDM1AMAOAMAOBNPC1RAB9A | |
| Methane SCHEMBL28950908 | 0.71 | KDM1A (0.30) | KDM1AMAOAMAOB | |
| Methane SCHEMBL28793204 | 0.68 | NPC1 (0.40) | KDM1AMAOAMAOBNPC1RAB9A | |
| SCHEMBL6863747 | 0.67 | MAOA (0.37) | KDM1AMAOAMAOBNPC1RAB9A | |
| SCHEMBL14491867 | 0.64 | NPC1 (0.43) | NPC1RAB9AALDH1A1LMNAHPGD | |
| SCHEMBL28096454 | 0.64 | NPC1 (0.47) | NPC1RAB9AALDH1A1LMNAHPGD | |
| SCHEMBL21523846 | 0.63 | SIGMAR1 (0.41) | NPC1RAB9AALDH1A1LMNAHPGD | |
| Biphenyl SCHEMBL4840882 | 0.62 | ALDH1A1 (0.60) | MAOAALDH1A1HPGDSLC6A4 | |
| Biphenyl SCHEMBL27882978 | 0.62 | ALDH1A1 (0.60) | MAOAALDH1A1HPGDSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329676-B2 | Cycloalkane-containing sphingosine 1-phosphate agonists | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-12-11 | — | — | US | disclosed |
| US-20110245204-A1 | CYCLOALKANE-CONTAINING SPHINGOSINE 1-PHOSPHATE AGONISTS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2011-10-06 | — | — | US | disclosed |
| US-20100112037-A1 | S1P RECEPTOR AGONISTS FOR THE TREATMENT OF CEREBRAL MALARIA | LEXICON PHARMACEUTICALS, INC. | 2010-05-06 | — | — | US | disclosed |
| US-20090062238-A1 | METHOD FOR TREATMENT OF NEUROPATHIC PAIN | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245204-A1 | CYCLOALKANE-CONTAINING SPHINGOSINE 1-PHOSPHATE AGONISTS | S1PR1, S1PR3, S1PR4 | KDM1A 3861/4885MAOA 4442/4885MAOB 4321/4885 |
| US-20100112037-A1 | S1P RECEPTOR AGONISTS FOR THE TREATMENT OF CEREBRAL MALARIA | S1PR1, S1PR2, S1PR3 | KDM1A 3270/4885MAOA 2782/4885MAOB 2111/4885 |
| US-20090062238-A1 | METHOD FOR TREATMENT OF NEUROPATHIC PAIN | S1PR2, S1PR1, S1PR4 | KDM1A 3357/4885MAOA 2859/4885MAOB 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.